Literature DB >> 29980507

Positive Results for Tazemetostat in Follicular Lymphoma.

.   

Abstract

A recently reported clinical trial indicates that the EZH2 inhibitor tazemetostat is effective against relapsed or refractory follicular lymphoma. Three of 28 patients with EZH2 mutations had complete responses, and 17 had partial responses. ©2018 American Association for Cancer Research.

Entities:  

Year:  2018        PMID： 29980507     DOI： 10.1158/2159-8290.CD-NB2018-088

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  2 in total

Review 1.  Finding an easy way to harmonize: a review of advances in clinical research and combination strategies of EZH2 inhibitors.

Authors:  Chen Li; Yan Wang; Yueqing Gong; Tengrui Zhang; Jiaqi Huang; Zhen Tan; Lixiang Xue
Journal:  Clin Epigenetics       Date:  2021-03-24       Impact factor: 6.551

2.  EZH2 inhibits NK cell-mediated antitumor immunity by suppressing CXCL10 expression in an HDAC10-dependent manner.

Authors:  Suresh Bugide; Romi Gupta; Michael R Green; Narendra Wajapeyee
Journal:  Proc Natl Acad Sci U S A       Date:  2021-07-27       Impact factor: 11.205
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.